Did you know that early newborn screening saves lives every year?
Blood tests, using a few drops of blood from a newborn's heel, can help detect genetic, endocrine, and metabolic disorders and defects allowing for early intervention and preventing death and disability.
CLSI newborn screening laboratory standards and products provide important test collection instructions, as well as information on methods for the detection of metabolic and hereditary disorders.
Dried Blood Spot Specimen Collection for Newborn Screening, 7th Edition
This standard highlights specimen collection methods, discusses acceptable techniques for applying blood drops or aliquots to the filter paper section of the specimen collection device, and provides instructions on proper specimen drying, handling, and transport to ensure quality specimens are consistently obtained for newborn screening analysis.
Newborn Screening for Hemoglobinopathies, 1st Edition
This guideline describes the recommended protocols for detecting hemoglobinopathies and thalassemias by population-based newborn screening using dried blood spot specimens. Early, presymptomatic detection to identify newborns with abnormal hemoglobins is critical because it improves treatment effectiveness.
Latest Insights: September is Newborn Screening Awareness Month
In 1963, as a result of a discovery by Dr. Robert Guthrie, newborns could finally be screened and receive treatment for a disease before symptoms appeared. Dr. Guthrie and his colleague published a paper outlining their discovery.
Newborn screening (NBS) is an important component of public health that helps health care providers identify hereditary and metabolic disorders in newborns and enables early therapeutic intervention, which can be lifesaving or altering. Newborn screening programs are typically state- or country-based public health programs. Today, newer and more complex technology is increasingly being integrated into NBS.
Prenatal screening tests are performed during pregnancy to determine the likelihood of a baby having specific birth defects. Most tests are performed during the first or second trimester and are noninvasive.
Improving Accuracy of Newborn Screening for Cystic Fibrosis
Cystic fibrosis newborn screening accuracy is essential for early diagnosis and treatment, which has been shown to improve outcomes. In a seven year study of 16 sibling pairs with cystic fibrosis, it was found that early initiation of therapy (before age 1) was beneficial.
Newborn blood spot screening is the practice of testing newborns for certain harmful or potentially fatal diseases that aren't apparent at birth. A simple blood test can diagnose these rare conditions.